Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis

References

• Dougados M, van der Linden S, Juhfin R, Huitfeldt B, Amor B, CalM A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34:1218–27.
   PubMed Web of Science ®Google Scholar
• Khan MA, van der Linden SM. Ankylosing spondylitis and other spondyloarthropathies. Rheum Dis Clin North Am. 1990;16: 551–79.
   PubMed Web of Science ®Google Scholar
• Chou CT. HLA-B27 and other related genes in ankylosing spondylitis in APLAR countries. APLAR J Rheumatol. 2005;8:143–5.
   Google Scholar
• Gonzalez-Roces S, Alvarez MV, Gonzalez S, Dieye A, Makni H, Woodfield DG, et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens. 1997;49: 116–23.
   Google Scholar
• Stunock RD, Hart FD. Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondyli-tis. Ann Rheum Dis. 1974;33:129–31.
   PubMedGoogle Scholar
• Chen J, Liu C. Is sulfasalazine effective in ankylosing spondy-litis? A systematic review of randomized controlled trials. J Rheumatol. 2006;33:722–31.
   PubMed Web of Science ®Google Scholar
• Toussirot E, Lafforgue P, Boucraut J, Despieds P, Schiano A, Bernard D, et al. Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int. 1994;13:175–80.
   PubMed Web of Science ®Google Scholar
• Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994;33:927–31.
   PubMedGoogle Scholar
• Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy speci-mens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499–505.
   PubMed Web of Science ®Google Scholar
• Gu J, Kuipers J, Maerker-Hermann E, Yu D. Microarray gene expression profiles in spondyloarthropathy (SPA) mirror disease mediating processes [abstract]. Arthritis Rheum. 2000;43(Suppl 9):S396.
   Google Scholar
• Brandt J, Haibel H, Comely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody inflix-imab. Arthritis Rheum. 2000;43:1346–52.
   PubMed Web of Science ®Google Scholar
• Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spon-dylitis by inhibition of tumor necrosis factor-a. N Engl J Med. 2002;346:1349–56.
   Google Scholar
• Davis JC, van der Heijde D, Braun J, Douquados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum. 2003;48:3230–6.
   PubMed Web of Science ®Google Scholar
• CalM A, Dijkmans BAC, Emery P, Kalden J, Leirisalo-Repo M, Mola EM, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004;63:1594–600.
   Google Scholar
• Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis. Part II: Biological therapies in the spondyloarthri-tides. Scand J Rheumatol. 2005;34:178–90.
   PubMed Web of Science ®Google Scholar
• Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rud-waleit M, et al. Long- term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology. 2005;44:342–8.
   Google Scholar
• Sieper J, Barafiakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology. 2005;44:1525–30.
   PubMed Web of Science ®Google Scholar
• Heijde D, Kivitz A, Schiff M, Sieper J, Dijakmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with anky-losing spondylitis. Arthritis Rheum. 2006;54:2136–46.
   PubMedGoogle Scholar
• Lambert R, Salonen D, Rahman P, Inman RD, Wong RL, Ein-stein SG, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spon-dylitis. Arthritis Rheum. 2007;56:4005–14.
   Google Scholar
• Choi CB, Kim TJ, Park HJ, Uhm WS, Jun JB, Bae SC, et al. Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy. J Korean Med Sci. 2008;23:852–6.
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324–31.
   PubMed Web of Science ®Google Scholar
• Van der Linden SM, Valkenburg HA, Cast A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Baron G, van der Heijde D, Felson DT, Douquados M. Ankylosing spondylitis assessment group preliminary defini-tion of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44:1876–86.
   Google Scholar
• CalM A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in anky-losing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.
   Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, CalM A, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91.
   PubMed Web of Science ®Google Scholar
• Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003;62:817–24.
   Google Scholar
• Wei JC, Wong RH, Huang JH, Yu CT, Chou CT, Jan MS, et al. Evaluation of internal consistency and re-test reliability of bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan. Clin Rheumatol. 2007;26:1685–91.
   PubMed Web of Science ®Google Scholar
• Howe HS, Zhao L, Song YW, Springer L, Edmonds J, Gu J, et al. Seronegative spondyloarthropathy—studies from the Asia pacific region. Ann Acad Med Singapore. 2007;36:135–41.
   PubMedGoogle Scholar
• Feltkamp TE, Mardjuadi A, Huang F, Chou CT. Spondyloarthr-opathies in eastern Asia. Curr Opin Rheumatol. 2001;13:285–90.
   PubMed Web of Science ®Google Scholar
• Chou CT. The clinical application of etanercept in Chinese patients with rheumatic disease. Mod Rheumatol. 2006;16: 206–13.
   PubMedGoogle Scholar
• Huang F, Gu J, Zhao W, Zhu J, Zhang J, Yu DT. One-year-open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum. 2002;47:249–54.
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, for the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582–91.
   Google Scholar
• Davis JC, Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spon-dylitis and improvements with etanercept therapy. Arthritis Rheum. 2005;53:494–501.
   PubMed Web of Science ®Google Scholar
• Visvanathan S, Wagner CL, Marini JC, Baker D, Gathany T, Han J, et al. Inflammatory biomarkers, disease activity, and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis. 2008;67:511–7.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Brandt J, Listing J, Haibel H, Sorensen H, Rudwaleit M, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum. 2005;53:856–63.
   PubMed Web of Science ®Google Scholar